After years of scrutiny over his handling of a high-profile drug program, former CytoDyn chief executive Nader Pourhassan is headed to federal prison.
A federal judge in Maryland on Monday sentenced Pourhassan to 30 months behind bars after a jury convicted him of securities fraud, wire fraud, and insider trading. The court also ordered him to pay more than $5.3 million in restitution and to forfeit roughly $4.4 million. The sentence caps a multi-year case that prosecutors say centered on misleading statements about the company’s drug program and millions of dollars in improper stock sales.
The U.S. Attorney’s Office for the District of Maryland detailed the penalties in a Jan. 26 press release, saying Pourhassan sold roughly 4.8 million shares and took in about $4.4 million from those trades. Prosecutors accused him of a pattern of public statements that, in their view, pumped up CytoDyn’s stock price and helped draw in fresh investors. For the official breakdown of the sentence and financial orders, see the announcement from the U.S. Attorney’s Office, District of Maryland.
How Prosecutors Say The Scheme Worked
Federal court filings and civil charges from securities regulators say Pourhassan repeatedly overstated the progress of CytoDyn’s drug candidate leronlimab toward Food and Drug Administration approval. That included a 2020 announcement that falsely claimed a completed Biologics License Application had been submitted to the agency.
Regulators and prosecutors pointed to those statements as key moments that moved CytoDyn’s stock price and attracted additional investment into the company. For background on the Securities and Exchange Commission’s civil case and its allegations, see the SEC.
Co-Defendant’s Case Takes A Different Turn
Pourhassan was tried alongside Kazem Kazempour, the former CEO of Amarex Clinical Research LLC, the contract research firm that worked with CytoDyn. Kazempour’s lawyers argued that presenting the two defendants together unfairly tainted their client in the eyes of the jury.
In a Jan. 16 order, a federal judge agreed in part, granting Kazempour a new trial and vacating two counts against him based on what the court described as prejudicial spillover, according to a statement from his defense team. That decision leaves Pourhassan’s sentence as the major resolved outcome so far, while Kazempour prepares to fight the remaining charges at a separate trial. More on the post-trial ruling is available from McGuireWoods.
Portland-Area Tie And Investor Fallout
Pourhassan, a resident of Lake Oswego, led Vancouver-based CytoDyn through aggressive publicity and fundraising efforts that prosecutors say pulled in roughly $300 million from investors. Local business watchers are now taking stock of what the criminal case and the financial penalties could mean for those who bought into the company’s story.
Regional coverage of the sentencing, and its impact on investors, ran in the Portland Business Journal. Shareholders and patients who followed leronlimab’s trajectory are now watching to see how restitution, forfeiture and any appeals unfold in court.
What Comes Next
Restitution and forfeiture orders will move through federal channels, with any recovery distributed under court procedures for victim compensation. In public filings, CytoDyn has disclosed that it is dealing with investigations by the Department of Justice and the Securities and Exchange Commission and has warned that those matters could affect its finances and operations. For details, see the company’s recent filing with the SEC.
For prosecutors, Pourhassan’s sentence closes a chapter in a case they say illustrates how executives who exploit public health emergencies to enrich themselves can face criminal consequences.
